Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07046260 · ClinicalTrials.gov registry record

Prospective Study to Assess a Diagnostic Aid for Cancer

A clinical trial of Cancer, sponsored by Harbinger Health.

Recruiting
Registry status
1,650
Enrollment target
20
Study locations

NCT07046260: Recruiting study of Cancer, sponsored by Harbinger Health.

NCT07046260 is a study of Cancer that is actively recruiting participants, run by Harbinger Health. The registered enrollment target is 1,650 participants, below the 3,488-participant average among 615 other Cancer trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07046260, a study of Cancer, is actively recruiting participants, sponsored by Harbinger Health.

RECRUITING
Registry status
1,650 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to establish the performance of two blood-based diagnostic aid test for cancer detection in individuals presenting with symptoms, signs, or findings suggestive of cancer.

Primary Outcome

* Predictive value of the Harbinger multi-cancer (MC) test by each readout category. * Predictive value of the Harbinger GI test by each readout category.

Conditions Studied

Interventions

  • OTHER Blood sample collection

Study Locations (20)

Florida

  • Zoyla Almeida, MD PA - Coconut Creek
  • Azzi ENT and Facial Reconstructive Surgery - Jupiter
  • Prophase, LLC - Margate
  • Millennium Medical Research - Miami
  • Regis Clinical Research - Miami
  • Gastroenterology of Greater Orlando - Orange City
  • Millennium Physician Group - Port Charlotte
  • Stuart Oncology Associates - Stuart
  • Avita Clinical Research - Tampa

California

  • Southern California Research Center - Coronado
  • Palomar Health - Poway
  • South Coast Gynecologic Oncology - San Diego

Georgia

  • Cancer Center of Middle Georgia - Dublin
  • Pulmonary & Sleep Specialists of Northeast Georgia, P.C - Winder

Illinois

  • Christie Clinic - Champaign
  • Hope and Healing Cancer Services - Hinsdale

Colorado

  • Rocky Mountain Gastroenterology - Centennial

Iowa

  • Iowa Clinic - West Des Moines

Kansas

  • Hutchinson Clinic - Hutchinson

Louisiana

  • Northlake Gastroenterology Associates - Hammond

Trial Details

FieldValue
Enrollment Target 1,650 participants
Start Date 2025-07-11
Est. Completion 2026-11
Harbinger Health

3 total trials

What NCT07046260 shows while recruiting

NCT07046260 is an observational study that tracks outcomes without assigning an intervention. Its 1,650 participants enrollment target places it among the larger protocols in the corpus, below the 3,488-participant average among 615 other Cancer trials with a reported enrollment target (53% lower).

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood sample collection is the first listed.

NCT07046260 names 20 study sites across 8 states, led by Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT07046260 about?

NCT07046260 is a clinical study titled "Prospective Study to Assess a Diagnostic Aid for Cancer". The primary objective of this study is to establish the performance of two blood-based diagnostic aid test for cancer detection in individuals presenting with symptoms, signs, or findings suggestive of cancer.

What is the current status of trial NCT07046260?

This trial is currently recruiting. The enrollment target is 1,650 participants. The study started on 2025-07-11. Estimated completion is 2026-11.

What conditions does trial NCT07046260 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT07046260?

The interventions under investigation include: Blood sample collection (OTHER).

Who is sponsoring clinical trial NCT07046260?

This trial is sponsored by Harbinger Health, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07046260 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07046260's enrollment target sits among peer trials

1,650 65th of 615 higher than 551 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04510129 · 1,650 participants

    A Multicenter Cancer Biospecimen Collection Study

  • NCT05612750 · 1,650 participants · NA

    Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study

  • NCT06215716 · 1,650 participants · Phase 3

    A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

  • NCT06401330 · 1,656 participants · Phase 3

    A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07046260, the US trial registry maintained by the National Library of Medicine. NCT07046260 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.